ALFERIEV, IVAN,CHORNY, MICHAEL,BRODEUR, GARRETT M.
申请号：
CA3056253
公开号：
CA3056253A1
申请日:
2018.03.13
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
Aco-drug is represented by Formula (I) or Formula (II), R-X-NH-CO-CO-OR1 (I) R-X-CO-O-CH2-CO-OR1 (II) where R is a tocol moiety, a tocol analog moiety, or a capsaicinoid moiety； X is a direct bond or a linking group； and OR1 is the residue of an anticancer or antirestenotic agent bearing at least one hydroxyl group by which the CO-OR1 ester linkage is formed. Nanoparticles that include the abovementioned co-drug are also provided, as well as a method of treating a cancer patient that includes administering an effective amount of the co-drug or nanoparticles.
